Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 104

Sort by

Sort Order Select

Journal Articles

Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas

Marina Gerousi, Maria Fitopoulou, Malama Galanou, Philip Rock, Georgios Karakatsoulis, Anastasia Anastasiadou, Maria Karipidou, Anastasia Iatrou, Efthalia Karamanli, Nikolaos Vastarouchas, Paolo Ghia, Charles C Chu, Clive S Zent, Richard Burack, Anastasia Chatzidimitriou, Kostas Stamatopoulos

Blood (2024) 144 (Supplement 1): 3002.

https://doi.org/10.1182/blood-2024-207057

Published: 2024

Journal Articles

Comparative Analysis of T Cell Profiles in Splenic Small B-Cell Malignancies

Elisavet Vlachonikola, Antonios Mingos, Philip Rock, Glykeria Gkoliou, Marina Gerousi, Maria Fitopoulou, Nikolaos Pechlivanis, Maria Karipidou, Anastasia Iatrou, Malama Galanou, Efthalia Karamanli, Nikolaos Vastarouchas, Charles C Chu, Clive S Zent, Richard Burack, Anastasia Chatzidimitriou, Kostas Stamatopoulos

Blood (2024) 144 (Supplement 1): 3000.

https://doi.org/10.1182/blood-2024-209511

Published: 2024

Journal Articles

Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)

Clare B Heffernan, Charles C Chu, Jennifer E Bruno, Christine A Herne, Andrea M Baran, Ronald P Taylor, Paul M. Barr, Michael R. Elliott, Clive S Zent

Blood (2023) 142 (Supplement 1): 6548.

https://doi.org/10.1182/blood-2023-175019

Published: 2023

Journal Articles

Splenic B Cell Lymphoma Innate Immune Cells: Detection of Red Versus White Pulp Lymphoma Differences in NK Cell Populations By High-Parameter Flow Cytometry

Christine A Herne, Jennifer E Bruno, Andrea M Baran, Derick R Peterson, Audrey H Chung, Tim R Mosmann, Sally A Quataert, Andrew G Evans, Walter R Burack, Clive S Zent, Charles C Chu

Blood (2023) 142 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2023-181081

Published: 2023

Journal Articles

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

Blood (2023) 142 (Supplement 1): 174.

https://doi.org/10.1182/blood-2023-189835

Published: 2023

Journal Articles

The Role of Splenectomy in Management of Splenic B-Cell Lymphomas

William J Archibald, Andrea M Baran, Annalynn M Williams, Chauncey Syposs, Rabih M Salloum, Andrew G Evans, Clive S. Zent

Blood (2022) 140 (Supplement 1): 11964–11965.

https://doi.org/10.1182/blood-2022-165496

Published: 2022

Journal Articles

Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment

Christine A. Herne, Jennifer E. Bruno, Andrea M Baran, Derick R. Peterson, Tim R. Mosmann, Sally A. Quataert, Andrew G Evans, Charles C. Chu, Clive S. Zent

Blood (2022) 140 (Supplement 1): 3585–3586.

https://doi.org/10.1182/blood-2022-167563

Published: 2022

Journal Articles

Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Karl R. VanDerMeid, Paul M. Barr, Alyssa R. Williams, Sally A. Quataert, Clive S. Zent, Charles C. Chu

Blood (2022) 140 (Supplement 1): 4121–4122.

https://doi.org/10.1182/blood-2022-169403

Published: 2022

Journal Articles

Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Clive S. Zent, Jeremiah E. Moore, Paige C. Bloom, Charles C. Chu, Jennifer E. Bruno, Christine A. Herne, Andrea M Baran, Sally A. Quataert, Tim R. Mosmann, Ronald P. Taylor, Danielle S. Wallace, Michael R. Elliott, Paul M. Barr

Blood (2022) 140 (Supplement 1): 4171–4172.

https://doi.org/10.1182/blood-2022-162858

Published: 2022

Journal Articles

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Danielle S. Wallace, Andrea M. Baran, Jonathan W. Friedberg, Patrick M. Reagan, Carla Casulo, Mijamin Friend, Alyssa R. Williams, Peter D Dakin, Clive S. Zent, Paul M. Barr

Blood (2021) 138 (Supplement 1): 2640.

https://doi.org/10.1182/blood-2021-145490

Published: 2021

Journal Articles

Arrhythmia Burden in Patients with Indolent Lymphoma

Mujtaba Soniwala, DO, Saadia Sherazi, MBBS, MS, Susan Schleede, MS, Scott McNitt, MS, Tina Faugh, Jeremiah Moore, PharmD, Justin Foster, PharmD, Clive S. Zent, MD, Paul M. Barr, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD MSSc, Eugene Storozynsky, MDPhD, Ilan Goldenberg, MD, Carla Casulo, MD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140053

Published: 2020

Journal Articles

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

Charles C. Chu, PhD, Jonathan J. Pinney, PhD, Sara K. Blick-Nitko, MS, Andrea M. Baran, MS, Derick R. Peterson, PhD, Hannah E. Whitehead, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Karl R. VanDerMeid, BS, Michael Rusty Elliott, PhD, Clive S. Zent, MD

Blood (2020) 136 (Supplement 1): 45.

https://doi.org/10.1182/blood-2020-139483

Published: 2020

Journal Articles

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Shuo Ma, MD PhD, Clive S. Zent, MD, Andrea M. Baran, MS, Andrew Bui, Philip J Meacham, PhD, Ashley Morrison, RN, Kelsey Holkovic, RN, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P. Miskin, MSc, Michael S. Weiss, Jonathan W. Friedberg, MD MSSc, Brian T. Hill, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-134818

Published: 2020

Journal Articles

Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance

Jonathan J. Pinney, Fátima Rivera-Escalera, Charles C. Chu, Hannah E. Whitehead, Karl R. VanDerMeid, Ashley M. Nelson, Michelle C. Barbeau, Clive S. Zent, Michael R. Elliott

Blood (2020) 136 (18): 2065–2079.

https://doi.org/10.1182/blood.2020005571

Published: 2020

Includes: Multimedia, Supplemental data

Journal Articles

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

Charles C. Chu, PhD, Jonathan J. Pinney, MS, Karl R. VanDerMeid, BS, Raquel Izumi, PhD, Veerendra Munugalavadla, PhD, Paul M. Barr, MD, Michael Rusty Elliott, PhD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 682.

https://doi.org/10.1182/blood-2019-124901

Published: 2019

Journal Articles

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Paul M. Barr, MD, Brian T. Hill, MD, Shuo Ma, MD PhD, Andrea M Baran, MS, Andrew Bui, Philip J Meacham, MS, Ashley Morrison, Jane L. Liesveld, MD, Deborah A Mulford, MD, Peter Sportelli, BS, Hari P Miskin, MSc, Michael S Weiss, Jonathan W. Friedberg, MD, Clive S Zent, MD

Blood (2019) 134 (Supplement_1): 360.

https://doi.org/10.1182/blood-2019-123404

Published: 2019

Journal Articles

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Blood (2018) 132 (22): 2389–2400.

https://doi.org/10.1182/blood-2018-06-855502

Published: 2018

Includes: Supplemental data

Journal Articles

Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

Anthony R. Mato, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, John N. Allan, MD, Danielle M. Brander, MD, John M. Pagel, MD PhD, Chaitra S. Ujjani, MD, Brian T. Hill, MD PhD, Nicole Lamanna, MD, Frederick Lansigan, MD, Ryan Jacobs, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Jeffrey J. Pu, MD PhD, Paul M. Barr, MD, Alison R. Sehgal, MD, Bruce D. Cheson, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Allison M. Winter, MD, Kaitlin Kennard, RN, BSN, Krista Isaac, DO, MS, Colleen Dorsey, BSN, RN, Alexandra Marie Vandegrift, BA, Arun K Singavi, MD, Annalynn Williams, MS, Christina Howlett, PharmD, Hanna Weissbrot, BS, Naveed Ali, MD, Sirin Khajavian, MD, Andrea Sitlinger, MD, Eve Tranchito, BS, Joanna Rhodes, MD, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Bhavisha Patel, MD, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Chadi Nabhan, MD MBA, FACP

Blood (2017) 130 (Supplement 1): 4315.

https://doi.org/10.1182/blood.V130.Suppl_1.4315.4315

Published: 2017

Journal Articles

Real-World Evidence for Durable Treatment Responses after Toxicity Related Discontinuation of Idelalisib

Blood (2017) 130 (Supplement 1): 4325.

https://doi.org/10.1182/blood.V130.Suppl_1.4325.4325

Published: 2017

Journal Articles

Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

Anthony R. Mato, MD, John N. Allan, MD, John M. Pagel, MD PhD, Danielle M. Brander, MD, Brian T. Hill, MD PhD, Bruce D. Cheson, MD, Richard R. Furman, MD, Nicole Lamanna, MD, Constantine S. Tam, MBBS, MD FRACP, FRCPA, Ryan Jacobs, MD, Frederick Lansigan, MD, Paul M. Barr, MD, Mazyar Shadman, MD, Alan P Skarbnik, MD, Douglas F. Beach, MD, Jeffrey J. Pu, MD PhD, Alison R. Sehgal, MD, Allison M. Winter, MD, Clive S Zent, MD, Hande H. Tuncer, MD, Arun K Singavi, MD, Stephen J. Schuster, MD, Peter V. Pickens, MD, Nirav N Shah, MD, Annalynn Williams, MS, Christina Howlett, PharmD, BCOP, Hanna Weissbrot, BS, Naveed Ali, MD, Bhavisha Patel, MD, Krista Isaac, DO, MS, Joanna Rhodes, MD, Mitchell E. Hughes, PharmD, BCPS, BCOP, Sirin Khajavian, MD, Elizabeth T Chatburn, BS, Andrea Sitlinger, MD, Eve Tranchito, BS, Erica Bharat Bhavsar, BS, Neil Bailey, MS, Timothy F. Burns, MD, Melissa Yacur, MD, Mansi Malhotra, BS, Sasanka Handunnetti, MD, Kaitlin Kennard, RN, BSN, Chadi Nabhan, MD MBA, FACP, Chaitra S. Ujjani, MD

Blood (2017) 130 (Supplement 1): 3011.

https://doi.org/10.1182/blood.V130.Suppl_1.3011.3011

Published: 2017

NARROW

Distinct Signaling Profiles in Primary Splenic Small B-Cell Lymphomas

Comparative Analysis of T Cell Profiles in Splenic Small B-Cell Malignancies

Low Dose Rituximab Efficiently Clears Circulating CLL Cells and Maintains Sensitivity to Antibody Dependent Cellular Phagocytosis (ADCP)

Splenic B Cell Lymphoma Innate Immune Cells: Detection of Red Versus White Pulp Lymphoma Differences in NK Cell Populations By High-Parameter Flow Cytometry

DNA Methylation-Based Classification of Hairy Cell Leukemia and Splenic B Cell Lymphoma

The Role of Splenectomy in Management of Splenic B-Cell Lymphomas

Innate Immune Microenvironment of Indolent B Cell Splenic Lymphomas: Role in Diagnosis and Treatment

Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Arrhythmia Burden in Patients with Indolent Lymphoma

Ibrutinib Off-Target Inhibition Inhibits Antibody-Dependent Cellular Phagocytosis but Not Efferocytosis of CLL Cells

A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Macrophage hypophagia as a mechanism of innate immune exhaustion in mAb-induced cell clearance

Anti-CD20 Therapy Reliance on Antibody-Dependent Cellular Phagocytosis Affects Combination Drug Choice

A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels

Disease and Patient Characteristics, Patterns of Care, Toxicities, and Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients Treated with Venetoclax: A Multicenter Study of 204 Patients

Real-World Evidence for Durable Treatment Responses after Toxicity Related Discontinuation of Idelalisib

Front-Line Ibrutinib Therapy for Chronic Lymphocytic Leukemia (CLL) in the Real World: Responses, Toxicity, Outcomes and Subsequent Therapies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only